Jason Williams is a Gastroenterology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
751 S Bascom Ave
Santa Clara Valley Medical Center
San Jose, CA 951282604
Telephone
408-885-7947Registry record last updated 3 Jul 2012.
Clinical trials
- Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
Sponsor: Williams Cancer Foundation
- Silicone Taping for the Improvement of Abdominal Donor Site Scars
Sponsor: Nova Scotia Health Authority
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ERBE USA IncProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
55.6%Rifamycin Antibacterial23.8%Xifaxan100%Part D<11 patientsProton pump inhibitor23.8%Omeprazole100%Part D≥16 patients+ 1 more class in this area
Anti-infectives
37.1%Nucleoside and nucleotide reverse transcriptase inhibitors23.2%Tenofovir Disoproxil Fumarate66%Vemlidy34%Part D<11 patientsHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor13.9%Entecavir100%Part D<11 patientsCardiovascular
7.3%Aldosterone antagonist (MRA)7.3%Spironolactone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”